Marizomib for patients with newly diagnosed glioblastoma : A randomized phase 3 trial
Roth, Patrick (Department of Neurology. University of Zurich)
Gorlia, Thierry (European Organisation for Research and Treatment of Cancer (EORTC))
Reijneveld, Jaap C. (Amsterdam UMC. University Medical Center)
De Vos, Filip (University Medical Center Utrecht)
Idbaïh, Ahmed (Sorbonne Université)
Frenel, Jean Sébastien (Institut de Cancerologie de L'Ouest)
Rhun, Emilie Le (University of Zurich)
Sepulveda, Juan Manuel (Instituto de Investigación Sanitaria Hospital 12 de Octubre (Madrid))
Perry, James (University of Toronto)
Masucci, G. Laura (Centre Hospitalier de l'Université de Montréal)
Freres, Pierre (Centre Hospitalier Universitaire de Liège)
Hirte, Hal (McMaster University (Canadà))
Seidel, Clemens (University Hospital Leipzig)
Walenkamp, Annemiek (University Medical Center Groningen)
Lukacova, Slavka (Aarhus University Hospital (Aarhus, Dinamarca))
Meijnders, Paul (University of Antwerp)
Blais, Andre (Université Laval (Canadà))
Ducray, Francois (Hospices Civils de Lyon, Université Claude Bernard Lyon 1)
Verschaeve, Vincent (Grand Hopital de Charleroi)
Nicholas, Garth (University of Ottawa)
Balañá, Carmen (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Bota, Daniela A. (University of California)
Preusser, Matthias (Medical University of Vienna)
Nuyens, Sarah (European Organisation for Research and Treatment of Cancer (EORTC))
Dhermain, Fréderic (University Hospital Gustave Roussy)
van den Bent, Martin (Brain Tumor Center at ErasmusMC Cancer Institute)
O'Callaghan, Chris J. (Queen's University)
Vanlancker, Maureen (European Organisation for Research and Treatment of Cancer (EORTC) University of Toronto)
Mason, Warren (University of Toronto)
Weller, Michael (University of Zurich)

Date:	2024
Abstract:	Background. Standard treatment for patients with newly diagnosed glioblastoma includes surgery, radiotherapy (RT), and temozolomide (TMZ) chemotherapy (TMZ/RT→TMZ). The proteasome has long been considered a promising therapeutic target because of its role as a central biological hub in tumor cells. Marizomib is a novel pan-proteasome inhibitor that crosses the blood-brain barrier. Methods. European Organisation for Research andTreatment of Cancer 1709/Canadian CancerTrials Group CE. 8 was a multicenter, randomized, controlled, open-label phase 3 superiority trial. Key eligibility criteria included newly diagnosed glioblastoma, age.
Rights:	Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	EORTC 1709 ; Glioma ; MGMT ; Proteasome inhibitor ; Randomized study
Published in:	Neuro-Oncology, Vol. 26, Núm. 9 (September 2024) , p. 1670-1682, ISSN 1523-5866

DOI: 10.1093/neuonc/noae053
PMID: 38502052

13 p, 766.2 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles